Rigel Pharmaceuticals Inc
NASDAQ:RIGL

Watchlist Manager
Rigel Pharmaceuticals Inc Logo
Rigel Pharmaceuticals Inc
NASDAQ:RIGL
Watchlist
Price: 36.85 USD -2.85% Market Closed
Market Cap: $668.8m

Operating Margin

42.2%
Current
Improving
by 45%
vs 3-y average of -2.9%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
42.2%
=
Operating Income
$119m
/
Revenue
$282.1m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
42.2%
=
Operating Income
$119m
/
Revenue
$282.1m

Peer Comparison

Country Company Market Cap Operating
Margin
US
Rigel Pharmaceuticals Inc
NASDAQ:RIGL
688.2m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
385B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
185.1B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
167.9B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.8B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.2B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.8B USD
Loading...

Market Distribution

Higher than 95% of companies in the United States of America
Percentile
95th
Based on 14 112 companies
95th percentile
42.2%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Rigel Pharmaceuticals Inc
Glance View

Market Cap
668.8m USD
Industry
Biotechnology

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company is headquartered in South San Francisco, California and currently employs 165 full-time employees. The company went IPO on 2000-11-29. The firm is engaged in discovering, developing and providing small molecule drugs that improve the lives of patients with hematologic disorders, cancer and rare immune diseases. The firm's research focuses on signaling pathways that are critical to disease mechanisms. The firm's product, TAVALISSE (fostamatinib disodium hexahydrate) tablets, the spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia (ITP). The Company’s product is also commercially available in Europe, the United Kingdom (UK) (TAVLESSE) and Canada (TAVALISSE) for the treatment of chronic ITP in adult patients. Its clinical programs include its interleukin receptor-associated kinase (IRAK) inhibitor program and a receptor-interacting serine/threonine-protein kinase (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company (Lilly).

RIGL Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
42.2%
=
Operating Income
$119m
/
Revenue
$282.1m
What is Rigel Pharmaceuticals Inc's current Operating Margin?

The current Operating Margin for Rigel Pharmaceuticals Inc is 42.2%, which is above its 3-year median of -2.9%.

How has Operating Margin changed over time?

Over the last 3 years, Rigel Pharmaceuticals Inc’s Operating Margin has increased from -88.4% to 42.2%. During this period, it reached a low of -88.4% on Sep 30, 2022 and a high of 42.2% on Sep 30, 2025.

Back to Top